Get the Stockscreener App
426.00
0.10%
0.43
After Hours:
410.00
-16.00
-3.76%
Vertex Pharmaceuticals Inc stock is traded at $426.00, with a volume of 1.92M.
It is up +0.10% in the last 24 hours and up +5.63% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$425.57
Open:
$428.48
24h Volume:
1.92M
Relative Volume:
1.06
Market Cap:
$109.22B
Revenue:
$11.39B
Net Income/Loss:
$3.64B
P/E Ratio:
30.45
EPS:
13.9904
Net Cash Flow:
$3.50B
1W Performance:
+1.39%
1M Performance:
+5.63%
6M Performance:
-15.00%
1Y Performance:
-9.58%
1-Day Range:
$418.60
$430.10
1-Week Range:
$415.00
$430.10
52-Week Range:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals (VRTX) Reports Strong Q3 2025 Earnings with 11% Revenue Growth - GuruFocus
Vertex Pharmaceuticals Reports Strong Q3 2025 Results - TipRanks
Vertex Reports Third Quarter 2025 Financial Results - BioSpace
Vertex Pharmaceuticals Outpaces Expectations With Fresh Growth - Finimize
Vertex’s cystic fibrosis sales beat expectations, as newer drugs miss - The Boston Globe
Vertex Pharmaceuticals (VRTX) Beats Q3 Expectations, Shares Fall - GuruFocus
Earnings call transcript: Vertex Q3 2025 beats forecasts, stock gains - Investing.com
Why Vertex Skidded Despite Its Beat-And-Raise Quarter - Investor's Business Daily
Vertex falls despite Q3 double beats as 2025 revenue guidance narrowed - Seeking Alpha
Vertex’s Cystic Fibrosis Sales Beat, as Newer Drugs Miss - Bloomberg.com
Vertex Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Vertex Pharmaceuticals (VRTX) Q3 Earnings Surpass Expectations - GuruFocus
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Vertex Pharmaceuticals Grows Past Cystic Fibrosis With New Hits - Finimize
Vertex beats quarterly estimates on cystic fibrosis demand, new drugs - MSN
Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs - MarketScreener
Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations - Yahoo Finance
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book - MSN
After pain setback, Vertex spotlights renal portfolio in expectation-beating Q3 - FirstWord Pharma
Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Posts Q3 Adjusted EPS $4.80 per Share, vs. FactSet Est of $4.58 - MarketScreener
Earnings Flash (VRTX) Vertex Pharmaceuticals Posts Q3 Adjusted EPS $4.80, vs. FactSet Est of $4.58 - MarketScreener
Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
Vertex Pharma’s Stock Has Tumbled. Earnings Will Stop the Pain. - MSN
Visual analytics tools that track Vertex Pharmaceuticals Incorporated performanceWeekly Trade Report & Smart Investment Allocation Tips - newser.com
Is Vertex Pharmaceuticals Incorporated stock a safe investment in uncertain marketsJuly 2025 Macro Moves & Verified Entry Point Signals - newser.com
Published on: 2025-11-03 07:39:53 - newser.com
Can machine learning forecast Vertex Pharmaceuticals Incorporated recoveryPortfolio Update Report & Safe Capital Investment Plans - newser.com
Will Vertex Pharmaceuticals Incorporated benefit from macro trends2025 Analyst Calls & Growth Focused Entry Reports - newser.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Tredje AP fonden - MarketBeat
Telos Capital Management Inc. Increases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Torray Investment Partners LLC Grows Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Welch & Forbes LLC - MarketBeat
South Dakota Investment Council Sells 10,780 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Published on: 2025-11-03 04:36:10 - newser.com
Mission Wealth Management LP Reduces Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated’s volatility index tracking explainedEarnings Performance Report & Free AI Powered Buy and Sell Recommendations - newser.com
Exit strategy if you’re trapped in Vertex Pharmaceuticals IncorporatedMarket Activity Summary & Technical Pattern Based Buy Signals - newser.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Arkadios Wealth Advisors - MarketBeat
Vertex Pharmaceuticals (VRTX): Exploring Valuation After Promising Kidney Therapy Results and Growth in New Treatments - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Holdings Reduced by China Universal Asset Management Co. Ltd. - MarketBeat
Syverson Strege & Co Makes New $283,000 Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Keybank National Association OH Sells 1,523 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Published on: 2025-11-02 03:14:13 - newser.com
Momentum divergence signals in Vertex Pharmaceuticals Incorporated chartTrade Volume Report & Capital Protection Trade Alerts - newser.com
Vertex Pharmaceuticals (VRTX) Q3 Earnings: What To Expect - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Vertex Pharmaceuticals Incorporated (VRTX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
VERTEX PHARMACEUTICALS Earnings Preview: Recent $VRTX Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Top Biotech Stocks To Keep An Eye OnOctober 28th - MarketBeat
Fisher Funds Management LTD Has $5.74 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Lockheed Martin Investment Management Co. Purchases 2,760 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.47%
0.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):